



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16.

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, August 18th, 2017

To
The General Manager,
Listing Department,
Bombay Stock Exchange Limited,
1st Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001.

Dear Sir/Ma'am,

Sub: Outcome of the Board meeting – Regulation 30 of SEBI (LODR) Regulations, 2015.

Ref: Company Scrip Code: 524711


With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Friday, 18th August, 2017 at 04.30 P.M. at the Corporate office of the Company, interalia, considered and approved the following:

- i. Un-audited Financial Results for the quarter ended 30th June, 2017.
- ii. Limited Review Report for the quarter ended 30th June, 2017.
- iii. Draft Directors Report for the year ended 31st March, 2017.
- iv. MD and CFO Certification.
- v. Approval of Notice of the 26th Annual General Meeting for the Financial Year 2016-2017 to be held on Saturday, 23rd September, 2017 at 10.40 AM at Registered Office of the Company.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
for Vista Pharmaceuticals Limited

Chalapathirao Venkata Naraparaju
Wholetime Director
DIN: 03270178





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16.

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, August 18th, 2017

To
The General Manager,
Listing Department,
Bombay Stock Exchange Limited,
1st Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001.

Dear Sir/Ma'am,

Sub: Financial Results for the quarter ended 30th June, 2017 – Regulation 33 (3) (a).

Ref: Company Scrip Code: 524711


With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Friday, 18th August, 2017 at 04.30 P.M. at the Corporate office of the Company, interalia, considered and approved the un-audited Financial Results for the quarter ended 30th June, 2017.

Copy of Un-audited Financial Results for the quarter ended 30th June, 2017, along with copy of Limited Review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
for **Vista Pharmaceuticals Limited**

Chalapathirao Venkata Naraparaju
Wholetime Director
DIN: 03270178





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264


7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16.

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Statement Of Un-Audited Financial Results For The First Quarter Ended June 30, 2017			
(Rs. In Lacs)			
Sl. No.	Particulars	Quarter ended	
		30.06.2017	30.06.2016
		(Un Audited)	(UnAudited)
1	Revenue from operations		
	a) Net sales / income from operations	729.43	581.58
	b) Other Operating Income	-	-
	Total Revenue from operations	729.43	581.58
2	Other Income	-	-
3	Total Revenue (1 + 2)	729.43	581.58
4	Expenses		
	a) Cost of Materials consumed	423.06	402.19
	b) Changes in inventories	-	-
	c) Employee benefits expense	21.01	18.08
	d) Finance costs	40.37	21.39
	e) Depreciation and amortisation	25.38	26.07
	f) Manufacturing & Other expenditure	163.84	83.96
	Total expenses	673.65	551.69
5	Profit before tax (3 - 4)	55.78	29.89
6	Tax expense		
	a) Current tax	11.37	-
	b) Deferred tax	4.25	(2.31)
7	Profit for the period / year (5 - 6)	40.16	32.21
8	Other comprehensive income		
	a) (i) Items that will not be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-
	b) (i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-
	Total other comprehensive income	-	-
9	Total Comprehensive income (7 + 8)	40.16	32.21
10	Paid-up equity share capital	536.00	500.00
11	Other Equity	-	-
12	Earnings per equity share (face value Rs. 2/- each)		
	- Basic (Not Annualised)	0.15	0.13
	- Diluted (Not Annualised)	0.15	0.13

hs





Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16.

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

NOTES:

- 1 The above results were reviewed by the Audit Committee and taken on record and approved by the Board of Directors at their meeting held on 18th , August , 2017. The financial results for the Quarter Ended June 30, 2017 has been subjected to limited review by the company's Statutory Auditors.
- 2 The company has adopted Indian Accounting Standards(Ind AS) prescribed under section 133 of the Companies Act , 2013 read with the relevant rules issued thereunder. The date of Transition to Ind AS is April 01, 2017 and accordingly these unaudited financial results have been prepared in accordance with the recognition and measurements principles laid down in Ind AS 34 'Interim Financial Reporting" and the other accounting principles generally accepted in India .

Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter 30 June 2016

Particulars	Quarter Ended
	30.06.2016
	(UnAudited)
Net profit under previous GAAP	29.32
Impact on current and deferred taxes on Un absorbed business losses	2.31
Impairment of trade receivables due to expected credit loss model	0.57
Total Comprehensive Income under Ind AS	32.21


- 3 The financial results and other financial information for the Quarter ended 30 june , 2016 has been compiled by the management as per Ind AS , after exercising necessary due diligence , to ensure that the financial results provided true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.
- 4 There is possibility that these Quarterly financial results may require adjustment before constituting the final Ind AS financial Statements as of and for the year ending March 31st , 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of 1 or more optional exemptions from full restrospective application as permitted under Ind AS 101.
- 5 The Company operates in a single segment and the results pertain to a single segment.

For and on behalf of the Board of Directors

N.V.Chalapathi Rao

Director

Din No.03270178



Place: Hyderabad

Date: 18-08-2017



V KISHORE KUMAR & ASSOCIATES

Chartered Accountants

Limited Review Report on the Un-Audited Financial results


To
The Board of Directors
VISTA PHARMACEUTICALS LIMITED.

We have reviewed the unaudited financial results of VISTA PHARMACEUTICALS LIMITED, ("the company") for the quarter ended 30th June, 2017 which are included in the accompanying 'statement of unaudited financial Results for the quarter ended 30th June, 2017 together with the relevant notes thereon ("the statement"). The statement has been prepared by the company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulations, 2015 (the "Listing Regulations, 2015), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initialed by us for identification purpose. The statement is the responsibility of the company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquire of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards prescribed under section 133 of companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Kishore Kumar & Associates
Chartered Accountants
FRN: 013975S



V. Kishore Kumar
V. Kishore Kumar
Partner
M.No.222865

Place: Hyderabad
Date: 18/08/2017